Fig. 5: Nucleic acid biosynthesis and pathway intermediates in tamoxifen-resistant ILC cells. | Cell Death & Disease

Fig. 5: Nucleic acid biosynthesis and pathway intermediates in tamoxifen-resistant ILC cells.

From: Invasive lobular carcinoma: integrated multi-omics analysis reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance

Fig. 5

A Significantly enriched metabolic pathways in shASS1 vs. pLKO derivatives of MB134 and B SUM44 cell lines. C Changes in the levels of purine (dGMP, dGDP, GDP, GMP, IMP) and D pyrimidine (UDP, UMP, and CMP) nucleotides in parental (P) vs. tamoxifen-resistant (TAMR) MB134 cells. E Changes in the levels of purine (ATP and ADP, dGTP, GDP) and F pyrimidine (Cytosine, UMP) nucleotides in parental (P) vs. tamoxifen-resistant (TAMR) SUM44 cells. G Expression levels of PRPS1, H PAICS, and I DHODH in MB134 and SUM44 cell pairs as analyzed from RNA-seq data. (FPKM: Fragments Per Kilobase Per Million reads). J Representative picture of pCADS1859 (pCAD) levels in parental and TAMR cells and K in control (pLKO) vs. shASS1 derivatives of MB134 and SUM44 cell pairs. Bar diagrams show the average of more than one independent experiment (n = 2). ****p < 0.0001, ***p ≤ 0.001, **P ≤ 0.01, *p < 0.05.

Back to article page